Immunic (IMUX) Net Income (2013 - 2026)
Immunic (IMUX) posted Net Income of -$35.8 million for Q1 2026, up 74.96% sequentially from -$143.0 million in Q4 2025, and down 34.31% YoY from -$54.5 million in Q1 2025.
Powered by 
Analysis
Immunic (IMUX) Net Income (2013 - 2026) Analysis & Trends
Immunic has reported Net Income for 14 years, with the latest figure at -$35.8 million in Q1 2026.
- Quarterly Net Income fell 34.31% year-over-year to -$35.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$232.4 million (down 129.02% YoY) and the FY2025 annual result came in at -$222.1 million, down 4.87% from the prior year.
- Net Income climbed to -$35.8 million in Q1 2026 per IMUX's latest filing, from -$143.0 million in the prior quarter.
- Over five years, Net Income peaked at -$19.9 million in Q3 2022 and troughed at -$143.0 million in Q4 2025.
- A 5-year average of -$44.0 million and a median of -$26.6 million in 2023 frame the typical range for Net Income.
- The sharpest annual moves came in 2022 and 2024: Net Income slumped 497.2% in 2022, then jumped 79.29% in 2024.
- Over 5 years, Net Income stood at -$129.7 million in 2022, then advanced by 6.01% to -$121.9 million in 2023, then surged by 79.29% to -$25.2 million in 2024, then slumped by 466.57% to -$143.0 million in 2025, then soared by 74.96% to -$35.8 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$35.8 million, -$143.0 million, and -$26.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Immunic | 540.78 Mn | 540.78 Mn | - | -34.04 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -34.04 Mn |
| Mar 31, 2026 | -32.48 Mn |
| Dec 31, 2025 | -23.13 Mn |
| Sep 30, 2025 | -25.57 Mn |
| Jun 30, 2025 | -26.84 Mn |
| Mar 31, 2025 | -26.64 Mn |
| Dec 31, 2024 | -25.20 Mn |
| Sep 30, 2024 | -24.95 Mn |
| Jun 30, 2024 | -21.82 Mn |
| Mar 31, 2024 | -22.69 Mn |
| Dec 31, 2023 | -22.84 Mn |
| Sep 30, 2023 | -22.80 Mn |
| Jun 30, 2023 | -24.05 Mn |
| Mar 31, 2023 | -26.45 Mn |
| Dec 31, 2022 | -56.63 Mn |
| Sep 30, 2022 | -19.89 Mn |
| Jun 30, 2022 | -20.50 Mn |
| Mar 31, 2022 | -21.43 Mn |
| Dec 31, 2021 | -21.71 Mn |
| Sep 30, 2021 | -18.38 Mn |